fbpx Cochrane and BMJ questioned Tamiflu and Relenza effectivenes | Science in the net

Cochrane and BMJ questioned Tamiflu and Relenza effectivenes

di redazione
Pubblicato il 15/04/2014Read time: 2 mins

There is no good evidence about the effectiveness of Tamiflu (oseltamivir) and Relenza (zanamivir) for influenza prevention and treatment. This is the though claim made by Cochrane Collaboration and the British Medical Journal (BMJ), based on the extended systematic review they just published about the use of neuraminidase inhibitors against influenza.

Their study is entirely based on complete clinical study reports, trial registries, electronic databases, regulatory archives and correspondence with manufacturers, which correspond to more than 150,000 pages of documents; more specifically, the researchers focused on 20 (Tamiflu) and 26 (Relenza) randomized placebo controlled trials testing the effects of the drugs for treatment, prophylaxis, and post-exposure prophylaxis of influenza. Taken together, the trials analyzed involved more than 24,000 adults and children who had confirmed or suspected exposure to natural influenza.

What they found is that, when used for prophylaxis, both drugs reduce the proportion of symptomatic influenza (but not in children, for zanamivir). In spite of such a reduction, their effectiveness in preventing infected people to spread the disease to others remains unproven. Both drugs showed modest effects in terms of alleviation of influenza-like symptoms, but oseltamivir also increased the risk of nausea, vomiting, headaches, and renal and psychiatric syndromes. Whilst zanamivir reduces the proportion of patients with laboratory confirmed symptomatic influenza, no evidence has been found that the two drugs may decrease the risk of complications of influenza, particularly pneumonia, or the risk of hospital admission or death. Evidence also suggests that Tamiflu prevented some people from producing sufficient numbers of their own antibodies to fight infection.

Such a massive review was not possible in 2009, due to a lack of access to available trial data, and this prevented researchers from verifying the claims about the effectiveness of neuraminidase inhibitors against influenza complications, which in turns led to governments’ decision to stockpile these drugs in case of a pandemic. A decision that cost a huge amount of money and that raised many controversies.

The authors of the study concluded that their findings do not support the mode of action of the two drugs proposed by the manufacturers, and raise question about the global stockpiling of oseltamivir and its inclusion on the WHO list of essential drugs as an anti-influenza drug. According to authors, governments took such decisions “on the basis of a published evidence base that has been affected by reporting bias, ghost authorship, and poor methods”.


Scienza in rete è un giornale senza pubblicità e aperto a tutti per garantire l’indipendenza dell’informazione e il diritto universale alla cittadinanza scientifica. Contribuisci a dar voce alla ricerca sostenendo Scienza in rete. In questo modo, potrai entrare a far parte della nostra comunità e condividere il nostro percorso. Clicca sul pulsante e scegli liberamente quanto donare! Anche una piccola somma è importante. Se vuoi fare una donazione ricorrente, ci consenti di programmare meglio il nostro lavoro e resti comunque libero di interromperla quando credi.


  • 8353 reads

prossimo articolo

Discovered a New Carbon-Carbon Chemical Bond

di Chiara D'Errico
Pubblicato il 16/10/2024

A group of researchers from Hokkaido University has provided the first experimental evidence of the existence of a new type of chemical bond: the single-electron covalent bond, theorized by Linus Pauling in 1931 but never verified until now. Using derivatives of hexaarylethane (HPE), the scientists were able to stabilize this unusual bond between two carbon atoms and study it with spectroscopic techniques and X-ray diffraction. This discovery opens new perspectives in understanding bond chemistry and could lead to the development of new materials with innovative applications.

In the cover image: study of the sigma bond with X-ray diffraction. Credits: Yusuke Ishigaki

Chemistry

After nearly a year of review, on September 25, a study was published in Nature that has sparked a lot of discussion, especially among chemists. A group of researchers from Hokkaido University synthesized a molecule that experimentally demonstrated the existence of a new type of chemical bond, something that does not happen very often.